Wen Hui, Yang Jing, Zhang Jian-jun, Wang Ya-fang, Ji Cheng-xue, Yang Guang-zhong
Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Yao Xue Xue Bao. 2009 Mar;44(3):303-8.
Based on the pharmacophore information and the analysis of structure-activity relationship of SSRIs and SNRIs, a series of substituted aromatic heterocyclic arylamidine derivatives were designed and synthesized in order to search for lead compounds with dual activity. All of them were new compounds, and their structures were confirmed by 1H NMR and HRMS. Preliminary in vitro pharmacological tests showed that all target compounds exhibited 5-HT reuptake inhibitory activity and some compounds exhibited NE reuptake inhibitory activity. These aromatic heterocyclic arylamidine designed can be further optimized for finding more potent 5-HT/NE dual reuptake inhibitors and antidepressant candidates as well.
基于药效团信息以及对选择性5-羟色胺再摄取抑制剂(SSRIs)和5-羟色胺及去甲肾上腺素再摄取抑制剂(SNRIs)构效关系的分析,设计并合成了一系列取代芳香杂环芳脒衍生物,以寻找具有双重活性的先导化合物。它们均为新化合物,其结构经1H NMR和高分辨质谱(HRMS)确证。初步体外药理试验表明,所有目标化合物均表现出5-羟色胺再摄取抑制活性,部分化合物还表现出去甲肾上腺素再摄取抑制活性。所设计的这些芳香杂环芳脒可进一步优化,以找到更有效的5-羟色胺/去甲肾上腺素双重再摄取抑制剂以及抗抑郁候选药物。